Patents by Inventor Wyeth Wasserman

Wyeth Wasserman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20050244842
    Abstract: The present invention relates an isolated promoter region of the mammalian transcription factor FOXC2. The invention also relates to screening methods for agents modulating the expression of FOXC2 and thereby being potentially useful for the treatment of medical conditions related to obesity. The invention further relates to a previously unknown variant of the human FOXC2 gene, derived via the use of an alternative promoter, which produces an additional exon that generates a distinct open reading frame via splicing. The alternative gene encodes a variant of the FOXC2 transcription factor, which is lacking a part of the DNA-binding domain and consequently has a potential regulatory function.
    Type: Application
    Filed: October 22, 2004
    Publication date: November 3, 2005
    Inventors: Sven Enerback, Katarina Krook, Lena Rondahl, Wyeth Wasserman
  • Publication number: 20030143583
    Abstract: The present invention is directed to a novel Afx response element comprising the nucleotide sequence AACATGTT, said nucleotide sequence having a DNA binding site for the human fork head transkription factor Afx. The invention also relates to the use of the Afx response element in the screening for genes as diabetes drug targets and in the bioinformatic analysis of the human genome, said genes in turn being useful in other screening methods for compounds modifying the insulin receptor signaling pathway. A further aspect of the invention is a vector construct comprising the novel nucleotide sequence, a host cell transformed with said vector construct as well as the fusion protein expressed by said host cell.
    Type: Application
    Filed: October 1, 2002
    Publication date: July 31, 2003
    Applicant: Biovitrum AB, a Swedish corporation
    Inventors: Isabel Climent-Johansson, Karin Dahlman-Wright, Staffan Lake, Wyeth Wasserman
  • Patent number: 6472515
    Abstract: The present invention is directed to a novel Afx response element comprising the nucleotide sequence AACATGTT, said nucleotide sequence having a DNA binding site for the human fork head transkription factor Afx. The invention also relates to the use of the Afx response element in the screening for genes as diabetes drug targets and in the bioinformatic analysis of the human genome, said genes in turn being useful in other screening methods for compounds modifying the insulin receptor signaling pathway. A further aspect of the invention is a vector construct comprising the novel nucleotide sequence, a host cell transformed with said vector construct as well as the fusion protein expressed by said host cell.
    Type: Grant
    Filed: August 24, 2000
    Date of Patent: October 29, 2002
    Assignee: Biovitrum AB
    Inventors: Isabel Climent-Johansson, Karin Dahlman-Wright, Staffan Lake, Wyeth Wasserman
  • Publication number: 20020090707
    Abstract: The present invention relates an isolated promoter region of the mammalian transcription factor FOXC2. The invention also relates to screening methods for agents modulating the expression of FOXC2 and thereby being potentially useful for the treatment of medical conditions related to obesity. The invention further relates to a previously unknown variant of the human FOXC2 gene, derived via the use of an alternative promoter, which produces an additional exon that generates a distinct open reading frame via splicing. The alternative gene encodes a variant of the FOXC2 transcription factor, which is lacking a part of the DNA-binding domain and consequently has a potential regulatory function.
    Type: Application
    Filed: September 26, 2001
    Publication date: July 11, 2002
    Inventors: Sven Enerback, Katarina Krook, Lena Rondahl, Wyeth Wasserman